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Antibodies Resources Table 3 . Relationship between nitrotyrosine levels and characteristics of smokers. ELISA microarray analysis on the linear relationship between 3-nitrotyrosine levels for 24 plasma proteins against five clinical parameters that are associated with smoking, including years since quitting smoking, age of first cigarette, total number of years smoking, diastolic and systolic blood pressure (BP). The regression model used in the statistical analyses tests the hypothesis that all coefficients are equal to 0 (i.e., 0
). This analysis indicates that there is very poor association between the measured log-transformed nitrotyrosine signal intensity and the independent variables included in the model. Material Figure 2 . Immunoblot analysis of the 3-nitrotyrosine levels of plasma proteins. Plasma samples from individuals who had never smoked and or were current smokers were randomly selected and compared. A. Image of the immunoblot from ~30 to 250 kDa. B. Results from densitometric analysis spanning the bracketed area of the immunoblot that is shown in panel A. Columns and crossbars represent the median density and standard error, respectively, of all the individual lanes per group. The p value (0.009) shows the statistical difference between the two groups, and was determined using a t-test. Figure 3 . Nitrotyrosine levels are not associated with time-since-quitting in past smokers. ELISA microarray analysis of current nitrotyrosine levels for select, representative, plasma proteins in past smokers (red diamonds), graphed against the years since quitting. Data from current smokers (black triangles, on left side of graphs) and never smokers (blue squares, on right side of graphs) are also shown. The nitrotyrosine signal intensity (Y-axis) is graphed as the log-transformed data. Figure 4 . 3-nitrotyrosine levels in 24 plasma proteins from smokers with chronic obstructive pulmonary disease (COPD) and smokers without COPD (nonCOPD). The horizontal bars within the boxes represent the median values, the boxes extend to the 25 th and 75 th percentiles, and the whiskers extend to the 5 th and 95 th percentiles, and all individual values are shown as stated symbols. * The COPD group is significantly different (p<0.01) from NonCOPD group based on a Wilcoxon test. Figure 5 . A receiver operator characteristic (ROC) curve demonstrating the classification potential of integrating nitrotyrosine protein assay and clinical data. Key: AUC. Area under the ROC curve; BMI, body mass index; CP, ceruloplasmin; SP-A, surfactant protein A; PLSDA, partial least squares discriminant analysis.
Years
Supplementary Material
